Author Interviews, COVID -19 Coronavirus / 02.04.2020
COVID-19: Early Antiviral Treatment Linked To Reduced Severity and Improved Prognosis
MedicalResearch.com Interview with:
[caption id="attachment_53735" align="alignleft" width="161"]
Dr. Hongcui Cao[/caption]
Hongcui Cao, M.D.
State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases
National Clinical Research Center for Infectious Diseases
The First Affiliated Hospital
College of Medicine, Zhejiang University
Hangzhou, China
MedicalResearch.com: What is the background for this study?
Response: The proportion of severe novel coronavirus disease (COVID-19) cases has dropped significantly. Specifically, this number has decreased from 32.4% on January 28 to 21.6% in Wuhan and to 7.2% in other provinces of China on February. Measures such as strengthened medical support and centralized isolation greatly contributed to the improved circumstances, and laid a solid foundation for further enhancing the cure rate and reducing the mortality rate. However, there are still hundreds of severe patients dying every day. It is extremely important to make timely and efficient diagnosis and initiate treatment for severe patients.
Dr. Hongcui Cao[/caption]
Hongcui Cao, M.D.
State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases
National Clinical Research Center for Infectious Diseases
The First Affiliated Hospital
College of Medicine, Zhejiang University
Hangzhou, China
MedicalResearch.com: What is the background for this study?
Response: The proportion of severe novel coronavirus disease (COVID-19) cases has dropped significantly. Specifically, this number has decreased from 32.4% on January 28 to 21.6% in Wuhan and to 7.2% in other provinces of China on February. Measures such as strengthened medical support and centralized isolation greatly contributed to the improved circumstances, and laid a solid foundation for further enhancing the cure rate and reducing the mortality rate. However, there are still hundreds of severe patients dying every day. It is extremely important to make timely and efficient diagnosis and initiate treatment for severe patients.


Dr. Bin Cao[/caption]
Bin Cao, Yeming Wang, Guohui Fan,
Lianghan Shang, Jiuyang Xu, DingyuZhang, Chen Wang
on behalf of LOTUS-China Study Group
China-Japan Friendship Hospital; Wuhan Jintinyan Hospital;
Institute of Respiratory Medicine, Chinese Academy of Medical Science
MedicalResearch.com: What is the background for this study?
Response: In the past two months, the outbreak of Coronavirus Disease 2019 (COVID-19) has been spreading rapidly across the world. Science and technology is the most powerful weapon for human to fight against diseases, especially in such a pandemic setting. Seeking for effective antiviral medication is the most critical and urgent among the many scientific tasks in the pandemic.
At the most critical moment in the fight against COVID-19, Chinese clinical scientists have stepped forward under extremely difficult research conditions to carry out clinical trials in antiviral treatment including lopinavir–ritonavir and remdesivir, in a swift, decisive and effective manner. These trials have attracted worldwide attention.
Recently, the Lopinavir–ritonavir Trial for suppression of SARS-CoV-2 in China (LOTUS-China) has been completed, which, with great clinical significance, can provide strong evidence for the treatment of COVID-19 both in China and around the world.



Dr. Jeffrey Smith[/caption]
Jeffrey R. Smith, MD PhD
Department of Medicine, Division of Genetic Medicine
Vanderbilt-Ingram Cancer Center, and Vanderbilt Genetics Institute
Vanderbilt University Medical Center
Medical Research Service
Tennessee Valley Healthcare System, Veterans Administration
Nashville, TN
MedicalResearch.com: What is the background for this study?
Response: Roughly 20% of men with prostate cancer have a family history of the disease, and 5% meet criteria for hereditary prostate cancer. Although prostate cancer has the greatest heritability of all common cancers (twice that of breast cancer), extensive heterogeneity of its inherited causes has presented a considerable obstacle for traditional pedigree-based genetic investigative approaches. Inherited causes across, as well as within families are diverse.
This study introduced a new familial case-control study design that uses extent of family history as a proxy for genetic burden. It compared a large number of men with prostate cancer, each from a separate family with a strong history of the disease, to screened men with no personal or family history. The study comprehensively deconstructs how the 8q24 chromosomal region impacts risk of hereditary prostate cancer, introducing several new analytical approaches. The locus had been known to alter risk of prostate, breast, colon, ovarian, and numerous additional cancers.



